Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Plos One|February 15, 2013
Nebulized fibrinolytic agents improve pulmonary fibrinolysis but not inflammation in rat models of direct and indirect acute lung injuryJorrit J Hofstra, Alexander D Cornet, Paul J Declerck, et al.
Critical Care (London, England)|July 24, 2020
Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidenceFrank M P van Haren, Clive Page, John G Laffey, et al.
Trials|March 26, 2014
HEPBURN - investigating the efficacy and safety of nebulized heparin versus placebo in burn patients with inhalation trauma: study protocol for a multi-center randomized controlled trialGerie J Glas, Johannes Muller, Jan M Binnekade, et al.
The Lancet. Respiratory Medicine|January 25, 2021
Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trialBarry Dixon, Roger J Smith, Duncan J Campbell, et al.
British Journal of Clinical Pharmacology|February 2, 2022
Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): Protocol and statistical analysis plan for an investigator-initiated international meta-trial of prospective randomised clinical studiesFrank M P van Haren, John G Laffey, Antonio Artigas, et al.
Intensive Care Medicine Experimental|February 7, 2025
Can nebulised heparin reduce acute lung injury in patients with SARS‑CoV‑2 requiring advanced respiratory support in Ireland: the CHARTER‑Ireland phase Ib/IIa, randomised, parallel-group, open-label studyDavid Cosgrave, Bairbre McNicholas, Ciara Hanley, et al.
Journal of Clinical Medicine|March 29, 2020
Nebulized Heparin in Burn Patients with Inhalation Trauma-Safety and FeasibilityGerie J Glas, Janneke Horn, Jan M Binnekade, et al.
British Journal of Clinical Pharmacology|January 5, 2022
Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patientsFrank M P van Haren, Lex M van Loon, Anne Steins, et al.
British Journal of Clinical Pharmacology|December 30, 2020
INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studiesFrank M P van Haren, Alice Richardson, Hwan-Jin Yoon, et al.
Eclinicalmedicine|November 3, 2025
Efficacy of inhaled nebulised unfractionated heparin to prevent intubation or death in hospitalised patients with COVID-19: an investigator-initiated international meta-trial of randomised clinical studiesFrank M P van Haren, Sarah J Valle, Ary Serpa Neto, et al.
Pageof 3